Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NICE BUMP TODAY !!!!
What's going on????????
Some good news today.
Can't say I disagree with you at this point.
I agree. Looks like Brady answered your question directly with today's update.
How's everyone doing?
Brady mentioned in the last couple of interviews that the goal is to have it done this year (hopefully by the end or the summer).
Hey Kizer......did you get on the train before it left the station?
I'm aware if the split.....what I meant was, nothing's fundamentally changed with the company.
Answer this.....
How is BioCorrx (The company, not the stock price) in a worse position today than it was at any other point in the last year or so?
Are they closer to their goals or further away?
I just think some people are
panicking because they expected the grant to send the SP to the moon.
Nothing's changed people.
I think everyone here has lost track of the real goal/s.......FDA Approval and/or Buyout!
The grant only provides confidence that the company will stay afloat and also have the necessary funding to move the product towards approval.
I personally wasn't expecting the grant news to move the PPS that much. Investors want to invest in companies that make money. BioCorrx isn't a profitable company YET but I think we can all agree that changes if/when they possess an FDA Approved product.
Receiving the grant was a huge step in the right direction.......but in my opinion this is still a long play.
Also, the fear of dilution was always there......but hopefully receiving the grant money will be enough of a bridge to carry the company to FDA approval without the need to dilute shares.
Hey Alkermes!
Did ya see that?
Nice move Brady.
Sorry about that.
See link below.
https://ir.biocorrx.com/press-releases/detail/138
This will explain the NIDA Impact Scoring System from today's update.
Impact score of 27 is pretty good and very likely to be funded.
https://www.nlm.nih.gov/ep/FAQScores.html
Just curious.....
What's everyone's expectations for SP after grant is received?
Do you guys think the SP will move significantly, slightly or not at all?
Totally understood.
I'm not good enough at the stock picking game to start day trading so long plays are my flavor.
Best if luck to you pal....maybe we'll see you back in closer to FDA approval.
Really surprised to hear that the recent PR wasn't enough to bring you back in. It was the one missing piece.
Those investors clearly see the potential here and they know .20 will be considered a steal in a short time.
The Lucemyra approval was ENORMOUS!!! It bridges the gap between active opioid usage, detox and beginning Naltrexone treatment.
I honestly believe that this will be the leading path to recovery within 2 years.
Grabbed another 20k+ shares this morning. This cash infusion just solved the ONLY problem they had.
BICX LONG!!!!!
Yeah, I think Kizer was the heart of this board. Also, we're still months away from the next catalyst which will be grant approval and/or investor financing. I think everyone's just watching right now. I try to add a few thousand shares every week or so. For me, nothing's changed about the potential of this company/stock. Money's low, but it's always been low.
The only thing that's REALLY changed is the timeline for FDA approval. Otherwise, the country is still experiencing the same opioid crisis that it was last year and it's only getting worse. The need for something like this will only get bigger. The only obstacle as we all know is getting insurers to cover it........which is expected once it's FDA approved.
Still long over here.
PLEASE.....for the love of GOD!
Do. Not. Feed. The. Bear.
BINGO!!!!
Couldn't have said it better.
I'm still long.
Who's with me?
See what I mean Dream.
Hey Dream,
Don't mean to sound harsh but everyone on this board isn't on the same team. Some people are traders, others are investors. Some are short term and others for the long haul. Lastly, some benefit from decline.....others load up during stagnation. All I'm saying is that everyone here has individual motives (short & long term) and the best advice I can you is to do you due diligence and go with your gut. That's the only decision you'll ever be able to live with down the road. Just my opinion.
The RS has been planned since last year. If I remember correctly, during last year's conference call someone asked Lourdes about this and she said something to the effect of the RS possibly happening early in 2018.
The goal has always been to uplist in order to attract institutional investors. Also, I thought I read last year that the SP for NASDAQ Capital Markets needs to be $3....not $4. Can someone clarify this for me?
Having access to $10 mil solves the 'money woes' issue.
Of course insurance hasn't covered this already.....it's not FDA approved yet. Hence the reason the company is going through with all of this.
They could not be any closer or in a better position than they're in right now.
I'm personally pleased to see that they have access to funds to move forward. The current SP doesn't concern me at all......I just look at it like a good sale. I snatch up a few thousand shares whenever I can because as far as I'm concerned......NO aspect about the future of company has gotten worse and EVERYTHING has gotten better!
BICX LONG !!!!
Interesting article just released on NIDA's twitter page.
https://www.drugabuse.gov/news-events/news-releases/2018/02/medication-in-prison-associated-reductions-in-fatal-opioid-overdoses-after-release
I think we'll see more of a positive response to this PR over the next few days as this new info starts to make it's way to the OTC analyst. Articles lead to exposure. I think we also need Brady to do more interviews if possible. Our last 'big spike' in share price was just after the segment on Fox. I also think our next big catalyst will be when the IND is submitted and/or when we receive grant money from NIH. Remember last year's big spike came after Alpine invested money. Funding breeds confidence for many individual investors.....when the money comes in the SP will rise IMO.
This may be 'moment of truth' time for this stock. The singular reason we've all been interested/invested in BICX is because of the potential of getting FDA approval on BICX101 or BICX102. Pretty exciting to realize that we may be within weeks (or even days) of learning if that dream may soon be a reality.
This may sound like blind optimism but if next PR details encouraging news from the FDA, these may be the lowest prices we'll ever see this stock at again.
I read something on the FDAs website that said that minutes from PRE-IND meeting go out WITHIN 30 calendar days.
I'll try to find the link.
Just curious.....if you already sold because you didn't believe in the company/stock, then why would you get back in at any price?
Correct me if I'm wrong but it seems to me that you DO believe in the future of this company/stock...you just got a little impatient at the wrong time.
Hey Parker.
You must be so pissed that missed out on an opportunity to double your money by about a week or two.
That had to suck!
I'm hoping Brady and Co. use their time in front of the FDA to also discuss to potential and suggested direction for BICX101 as well. I understand that the sole purpose of the meeting is to gain insight on how to proceed with the implant in order to quickly obtain FDA approval. BUT.... if they can come out of this meeting with clear direction from the FDA on the implant AND the injection (even though it isn't fully developed yet) I think that would be a home run!
I've been thinking the same thing!!!
Just curious Parker.....how long have you been holding BICX?
BioCorRx Submits Pre-IND Package to FDA for its Naltrexone Implant, BICX102
DOWNLOAD AS PDF
DECEMBER 19, 2017
ANAHEIM, CA, Dec. 19, 2017 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that it has submitted its pre-Investigational New Drug (pre-IND) package to the U.S. Food and Drug Administration (FDA) for the Company's naltrexone implant, BICX102. BICX102 is the Company's sustained release naltrexone implant for the treatment of opioid and alcohol use disorders.
The submitted pre-IND package provides the FDA with current information on BICX102, as well as the proposed development plan. The purpose of the meeting is to review the development plan and to seek the agency’s guidance on further development and commercialization of BICX102.
This pre-IND submission follows BioCorRx's recent announcement that the FDA has granted the Company a Type-B pre-IND meeting scheduled for January 24, 2018. As previously announced, the National Institute on Drug Abuse (NIDA) has agreed to attend the pre-IND meeting for BICX102 with the FDA. NIDA and National Institute on Alcohol Abuse and Alcoholism (NIAAA) have also received the documents which were submitted to the FDA.
Brady Granier, CEO, President, and Director of BioCorRx, commented, “We are pleased that BioCorRx® will be starting out the New Year with a meeting with the FDA. The submission of the pre-IND package is a major step that BioCorRx® has completed in its efforts to bring BICX102 to market. We thank all of our advisors and consultants for their tireless efforts in putting together a package that we feel will lead to a very productive meeting. We are pursuing the 505(b)(2) regulatory pathway, which we believe will be a more rapid and cost-effective route to approval. We are pleased that both NIDA and NIAAA are involved in this process and we look forward to the meeting with the FDA
Where did I put those Twinkies?
Hilarious !!!!!!
Everyone loves Twinkies !